Pancreatic Ductal Adenocarcinoma (PDA) is characterized by abundant infiltration of tumor associated macrophages (TAMs). TAMs have been reported to drive resistance to gemcitabine, the front-line chemotherapy in PDA, though the mechanism of this resistance remains unclear. Profiling metabolite exchange, we demonstrate macrophages programmed by PDA cells release a spectrum of pyrimidine species. These include deoxycytidine, which inhibits gemcitabine through molecular competition at the level of drug uptake and metabolism.
Results:

Macrophage released pyrimidines confer gemcitabine resistance to PDA cells
To study metabolite crosstalk between macrophages and PDA cells, we generated tumor educated macrophages (TEMs) by polarizing murine bone marrow-derived macrophages (BMDMs) with PDA cell conditioned media (CM) (Fig. S1a) using a system previously established to mimic pancreatic TAMs in vivo (Zhang et al., 2017a; Zhang et al., 2017b) . In parallel, BMDMs were directed to a classically activated phenotype (i.e. M1) by treatment with lipopolysaccharide (LPS) or polarized to an alternatively activated phenotype (i.e. M2) by treatment with Interleukin 4 (IL4) (Van den Bossche et al., 2017) . After 48 hours, conditioned media from these cultures were profiled using liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS) metabolomics (Fig. 1a ). This analysis revealed accumulation of pyrimidine nucleosides and nucleobases in TEM media (Fig. 1b) . In contrast, we did not observe a similar profile for release of purine species. When PDA cells were then incubated in TEM CM, many of the accumulated pyrimidines were depleted from TEM media by PDA cells ( Fig. 1c ), suggesting a directional transfer of these metabolites. This observation was provocative for several reasons. First, pyrimidine release and their transfer among cells has neither been previously reported nor characterized. Further, the front-line chemotherapy for PDA is gemcitabine (Gem), a pyrimidine anti-nucleoside. Gem resistance has been linked to TAMs in PDA (Mitchem et al., 2013) , although the mechanism behind this link remains unclear.
Thus, we hypothesized that pyrimidine nucleosides released by TEMs may directly confer gem resistance to PDA cells. Accordingly, we ran gem dose response curves in the presence of TEM CM (Fig. 1d ). We observed a shift in gem sensitivity with TEM CM, and this result was reproducible across a large panel of cell lines, including primary human patient-derived cultures (Fig. 1e, Fig. S1b ). This observation was also true of TEMs generated from a murine macrophage cell line (Fig. 1f, Fig   S1c) . We further that observed TEM CM retained the ability to confer gem resistance after boiling or passage through a 3kDa cutoff filter ( Fig. 1 g,h) , providing evidence for a metabolite factor driving the chemoresistance phenotype.
To determine if pyrimidines found in TEM media confer gem resistance, we treated PDA cells with gem in the presence of a high concentration (100µM) of these nucleosides (Fig. 1i ). Among these, we found deoxycytidine (dC) uniquely blocked cytotoxic activity of gem in PDA cells, and, furthermore, that this response was dose dependent (Fig. 1j ). We then quantitated dC and other pyrimidines in TEM CM by mass spectrometry and observed them to be in the micromolar range ( Fig. 1k , Table S1 ). Importantly, we were able to phenocopy the gem-resistance activity of TEM CM by simply supplementing growth media with 3 µM dC ( Fig. 1l, m, Fig. S1d ), the concentration observed in TEM CM.
Pyrimidine release is a property of alternatively activated macrophage metabolism
In addition to TEMs, M2 macrophages also released dC (Fig. 1a) , and their media conferred gem resistance to PDA cells ( Fig. 2a ). Neither feature was observed for M1 macrophage media.
The release of pyrimidines from TEMs and M2 macrophages is a biosynthetic and bioenergetically intensive process. And, given the dichotomy between macrophage subtypes, we were interested in understanding how the metabolic programs were wired to facilitate pyrimidine release. The functional metabolism of classical macrophage subtypes and their preferred bioenergetic pathways has been previously characterized (Jha et al., 2015) . Antiinflammatory macrophages were reported to preferentially utilize mitochondrial respiration and fatty acid oxidation (FAO) (Vats et al., 2006) , which we also observed in pancreatic TEMs ( These results led us to examine macrophage intracellular metabolomic profiles, which showed a close but not complete correlation between M2 macrophages and TEMs (Fig. 2f ). Pathway enrichment analysis of differential metabolites indicated that nucleoside metabolism pathways were highly represented among those that distinguish TEMs and M2 macrophages from M1 macrophages (Table S2 ). To gain further insight, we carried out stable isotope tracing using uniformly labeled 13 C-Glucose. The necessity of using PDA conditioned media to polarize TEMs prevented sufficient label incorporation into TEM biosynthetic pathways, limiting our tracing analysis to M1 and M2 macrophages. Nevertheless, comparison between M1 and M2 macrophage metabolism was illuminating, and subsequently relevant in TEMs. Consistent with our bioenergetic profiling analysis ( Fig. 2b-e ), 13 C-Glucose fractional labeling patterns revealed increased glucose flux through the tricarboxylic acid (TCA) cycle in M2 macrophages ( Fig. 2g ), which facilitated TCA cycle anaplerosis ( Fig. 2h ) and ultimately pyrimidine biosynthesis ( Fig. 2i,   Fig. S2e ). Furthermore, M2 macrophages demonstrated an increased abundance of intercellular and extracellular de novo synthesized pyrimidines as compared to M1 macrophages ( Fig. 2j ), supporting the idea that pyrimidine release is a property of anti-inflammatory macrophages.
Overall, M2 macrophages exhibited a vastly increased biosynthetic capacity from glucose, relative to M1 macrophages ( Fig. S2f ).
We next sought to determine if targeting pyrimidine production by inhibiting nodes of glucose metabolism would impair the ability of TEMs to confer gem resistance ( Fig. 2k ). Limiting availability of glucose, inhibiting glycolysis with 2-deoxyglucose (2-DG), or blocking glucose incorporation into the oxidative arm of the pentose phosphate pathway with 6aminonicotinamide (6-AN) all inhibited the ability of TEM CM to modulate gem sensitivity in PDA cells . Importantly, these treatments had a minimal impact on TEM proliferative capacity ( Fig. S3d ). Similar results were obtained by directly disrupting key pyrimidine biosynthesis enzymes, Dhodh and Umps, using a genetic knockdown strategy ( Fig.   2o , Fig. S3e, f) . These results demonstrate the requirement of de novo pyrimidine biosynthesis for TEM CM to inhibit gem activity in PDA cells.
Deoxycytidine competitively inhibits gemcitabine uptake and metabolism
Gem is a prodrug that requires activation through phosphorylation before it can be inserted into DNA. The first step in this process, phosphorylation by deoxycytidine kinase (dCK), serves to trap gem inside the cell. Subsequently, monophosphorylated-gem undergoes di-, and triphosphorylation before incorporation into DNA, where it causes masked chain termination and ultimately cell death ( Fig. 3a) (Parker, 2009) . Given the structural similarity between dC and gem, we hypothesized that dC could act to inhibit gem activity through molecular competition.
To examine this, we measured levels of intra and extracellular gem in the presence or absence of dC and observed that dC treatment resulted in an accumulation of gem both inside and outside the cell (Fig. 3b, Fig S3g) . The intercellular accumulation suggested a lack of gem processing and incorporation into DNA. To test this, we further treated PDA cells with 3 Hradiolabeled gem in the presence or absence of dC and observed that dC treatment prevented gem incorporation into DNA (Fig. 3c ). These results suggest that dC is acting to decrease the effective concentration of gem and its activated species experienced by the cell.
Pyrimidine-based chemotherapies represent a large and well characterized class of drugs ( Fig.   3d ) (Parker, 2009 ). Based on data in Fig.3b , c, the protective mechanism(s) of dC should be limited to those pyrimidine-based chemotherapies that share uptake or metabolism properties.
To test this hypothesis, we first examined 5-fluorouracil (5-FU), a different class of pyrimidine nucleoside-based chemotherapy that is used for patients with PDA as a component of the combination chemotherapy FOLFIRINOX (Conroy et al., 2011) . We found that the cytotoxic activity of 5-FU in PDA cells is not impacted by TEM CM or dC ( Fig. 3e ,f, Fig. S3h ). Consistent with our model, the primary transporter utilized by 5-FU and the activating enzyme are distinct from those involved in dC uptake and metabolism (Table S3 ). We then tested a panel of other pyrimidine-based chemotherapies ( Fig. 3g-j) . We observed that the cytotoxic activity of 5-azadeoxycytidine, but not 5-aza-cytidine, Fialuridine or Trifluorothymidine, was inhibited by concurrent treatment with 3µM dC (Fig. 3d ). The transporters used by dC and the ribosebearing chemotherapies tested share a high degree of overlap ( Fig. S6c ). Among the distinctions, intracellular activation by dCK differentiates anti-pyrimidine chemotherapies that are inhibited by dC from those that are not. The results from this chemical profiling strategy suggest that TEM-derived dC is inhibiting the cytotoxic activity of gem in PDA cells by reducing the effective concentration through molecular competition at dCK, the rate limiting enzyme for gem activation.
Macrophages modulate gemcitabine response
We next sought to determine if macrophages in the tumor microenvironment in vivo contribute to gem resistance. To examine this, we utilized a syngeneic PDA tumor transplantation model in mice expressing a diphtheria toxin (DT) receptor under the Cd11b promoter (Zhang et al., 2017a) , which allows for selective, temporary depletion of myeloid cells (Fig. 4a ). Consistent with our hypothesis, we found the size of tumors treated with gem after depletion of myeloid cells to be decreased dramatically, as compared to single treatment or vehicle treated arms ( Fig. 4b ). The increased efficiency of gem in myeloid depleted tumors resulted in increased DNA damage, marked by γH2AX immunostaining (Fig 4c,d) . In contrast, at end point, differences in proliferation or apoptosis were not evident among the groups (Fig. S4a ). Further, consistent with our model on the role of TAM-derived dC, treatment with 5-FU-based chemotherapy in this model yielded no benefit from myeloid depletion ( Fig. S4b) .
To test the clinical benefit of targeting macrophages in combination with gem treatment, we treated a genetically engineered, autochthonous pancreatic cancer model (Kras +/LSL-G12D ;
Trp53 +/LSL-R172H ; Pdx1-Cre, known as KPC) with the Colony Stimulating Factor Receptor 1 (CSFR1) inhibitor AZD7507, which blocks the recruitment and activation of monocytes, in combination with gem. In this model, we observed prolonged survival compared to gem alone or control-treated mice (Fig. 4e ). In a cohort of patients with PDA who underwent surgery and adjuvant gem, we also found significantly better survival in those with a low macrophage signature compared to those with a high macrophage signature (median disease-specific survival 35.8 months and 20.3 months, respectively) (Fig 4f,g) . Additionally, macrophage high patients fare worse than macrophage low patients in absence of adjuvant therapy (Fig. S4c,d) ,
indicating additional challenges which may be posed by macrophages, such as immunosuppression (Zhang et al., 2017a; Zhu et al., 2014) .
In summary, our data demonstrate a previously undescribed mechanism of intra-tumoral metabolic crosstalk that promotes therapeutic resistance (Fig. 4h ). In pancreatic tumors, malignant PDA cells recruit and polarize macrophages into TAMs (Liou et al., 2015; Zhang et al., 2017b) . We found that TAMs impair the cytotoxic activity of the front-line chemotherapy gem through the release of dC. In the tumor, dC competes with gem based on their molecular similarity, and thereby reduces the therapeutic efficacy. Accordingly, since gem remains a backbone of the standard chemotherapy regimen for pancreatic cancer patients (Von Hoff et al., 2013) , strategies to inhibit the recruitment of macrophages or reprogram anti-inflammatory macrophages have potential to increase the utility of this well tolerated and mainstay therapy, as has already been seen with FOLFIRONOX (Nywening et al., 2016) .
Discussion: Pyrimidine biosynthesis is energetically costly, suggesting that release is a regulated process. Purines are well-established signaling molecules (Di Virgilio and Adinolfi, 2017) , and release of pyrimidine nucleosides at micromolar levels may suggest a similar function. Alternatively, metabolites and breakdown products of metabolism can act in a paracrine fashion to regulate metabolism, and these have important roles in physiology. Further, we and others have reported on examples of such processes among the cells in tumors (Lyssiotis and Kimmelman, 2017; Murray, 2016) . We propose that the mechanism we discovered using a tumor model system is a previously undescribed physiological process, in which anti-inflammatory macrophages provide another cell type with pyrimidines during normal development. Indeed, a potential insight for the role of pyrimidines comes from a system-wide genetic deletion of the dC salvage enzyme dCK in mice. In these animals, development of lymphocytes is grossly impaired, demonstrating a requirement for pyrimidine salvage during lymphocyte development (Austin et al., 2012; Toy et al., 2010) . Our data suggest that the source of the salvaged pyrimidines may be from macrophages. Furthermore, as TAMs release a panel of pyrimidine nucleosides, they may promote chemoresistance to other therapies. Accordingly, these insights may shift the paradigm of how we consider the evolution of chemoresistance to nucleoside-like drugs, not only in PDA, but potentially in many other tumor types where TAMs play an important role.
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Materials and Methods:
Cell Culture: C57B6/J PDA lines KPC MT-3 and MT-5, were kind gifts from Dr. David Tuveson, KPC28258 from Dr. Sunil Hingorani, and KPC7940 from Dr. Gregory Beatty. iKras*3 PDA cells were previously described (Zhang et al., 2017a). MiaPaCa2, Panc1, BXPC3, L929, and RAW264.7 cell lines were purchased from ATCC. PA-TU-8902 was purchased from DSMZ. UM patient-derived cell lines were generated from de-identified patient tumor samples (Li et al., 2007) , with the approval of the Institutional Review Board of the University of Michigan. All commercial cell lines were validated by STR profiling. All cells were maintained in high-glucose DMEM (Gibco) supplemented with 10% FBS (Corning), and routinely tested for mycoplasma contamination using MycoAlert (Lonza). iKras*3 PDA cells were additionally maintained in 1µg/mL doxycycline, and 1µg/mL doxycycline was added as a control to other conditions in experiments in which this cell line was used.
Conditioned medium: Conditioned medium was produced by changing cell media of >50% confluent plates, then removing the medium from cells after 48 hours of growth and filtering through a 0.45μm polyethersulfone membrane (VWR). Boiled conditioned media was warmed to 100°C for 15 minutes and the precipitate was filtered out. Size cutoff columns (EMD Millipore, UFC900308) were used to remove species larger than 3kDa from the medium. The filtered conditioned medium was then resuspended in DMEM to the original volume. Conditioned media was used at a 3:1 ratio with fresh media to avoid effects of nutrient/metabolite exhaustion.
L929 conditioned media was prepared by incubating confluent L929 cells in fresh media for 48 hours, then filtered through a 0.45μm polyethersulfone membrane.
Bone-marrow macrophage differentiation: Bone marrow was extracted from the femurs of C57B6/J mice as described (Celada et al., 1984) , and cultured in macrophage differentiation media (i.e. high-glucose DMEM (Gibco) supplemented with 10% FBS (Corning), Sodium Pyruvate (Gibco), Penicillin/Streptomycin (Gibco), and 30% L929 conditioned media) for 5 days, refreshing on day 3.
Macrophage polarization: Bone-marrow derived macrophages and RAW264.7 cells were polarized using either murine 10ng/mL M-CSF (Peprotech), 10ng/mL LPS (Enzo, ALX-581-011-L001), 10ng/mL murine IL-4 (Peprotech), or 75% PDA conditioned media. Macrophage subtypes were polarized from matched biological replicates.
Metabolite sample preparation: Metabolite extraction from medium samples was done by adding 1 mL of conditioned medium to 4 mL of cold (-80°C) 100% methanol, then clarified by centrifugation. Intercellular metabolite fractions were prepared from cells that were lysed with cold (-80°C) 80% methanol, then clarified by centrifugation. Metabolite levels of intercellular fractions were normalized to the protein content of a parallel sample, and all samples were lyophilized via speed vac. Dried metabolite pellets from cells or media were re-suspended in 35 μL 50:50 MeOH: H2O mixture for metabolomics analysis. 13 C-Glucose tracing was performed using glucose free DMEM (Gibco) supplemented with 10% dialyzed FBS (Gibco) and either 25mM 12 C glucose (Sigma) or uniformly labeled 13 C-glucose (Cambridge Isotopes). BMDM cultures were polarized with appropriate stimulus for 24 hours in normal media, then the media was replaced with 13 C or 12 C glucose labeling media and incubated overnight. Samples were then harvested and prepared as above.
Metabolomics: For steady state metabolite profiling, an Agilent 1290 UHPLC-6490 Triple Quadrupole (QqQ) tandem mass spectrometer (MS/MS) system was used. For negative ion acquisition, a Waters Acquity UPLC BEH amide column (2.1 x 100mm, 1.7µm) was used with the mobile phase (A) consisting of 20 mM ammonium acetate, pH 9.6 in water, and mobile phase (B) acetonitrile. The following gradient was used: mobile phase (B) was held at 85% for 1 min, increased to 65% in 12 min, then to 40% in 15 min and held for 5 min before going to initial condition and held for 10 min. For positive ion acquisition, a Waters Acquity UPLC BEH TSS C18 column (2.1 x 100mm, 1.7µm) was used with mobile phase (A) consisting of 0.5 mM NH4F and 0.1% formic acid in water; mobile phase (B) consisting of 0.1% formic acid in acetonitrile.
The following gradient was used: mobile phase (B) was held at 1% for 1.5 min, increased to 80% in 15 min, then to 99% in 17 min and held for 2 min before going to initial condition and held for 10 min. The column was kept at 40 ºC and 3 µL of sample was injected into the LC- The statistical significance test was done by a two-tailed t-test with a significance threshold level of 0.05.
For the 13 C glucose tracing studies, an Agilent 1260 UHPLC combined with a 6520 Accurate-Mass Q-TOF LC/MS was utilized. Agilent MassHunter Workstation Software LC/MS Data Acquisition for 6200 series TOF/6500 series QTOF (B.06.01) was used for calibration and data acquisition. A Waters Acquity UPLC BEH amide column (2.1 x 100mm, 1.7µm) was used with mobile phase (A) consisting of 20 mM NH4OAc in water pH 9.6, and mobile phase (B) consisting of acetonitrile. The following gradient was used: mobile phase (B) was held at 85% for 1 min, increased to 65% in 12 min, then to 40% in 15 min and held for 5 min before going to initial condition and held for 10 min. The column was at 40 ºC and 3 µL of sample was injected into were used to find best peaks and signals by manual inspection. Key parameters were: mass tolerance = 20 or 10 ppm and RT tolerance = 1 or 0.5 min. Isotopologue ion thresholds and the anchor ion height threshold was set to 250 counts and the threshold of the sum of ion heights to 500 counts. Coelution correlation threshold was set to 0.3.
All other bioinformatics analyses including graphs and plots were done using R/Bioconductor. Chemicals: Gemcitabine, 5-azacytidine, decitabine, fialuridine, trifluorouridine, capecitabine, and 5-fluorouracil were sourced from Cayman Chemical. 6-Aminonicotinamide, 2-deoxyglucose, and all nucleosides and nucleotides were obtained from Sigma-Aldrich. Compounds were dissolved into PBS (Gibco) and added to media to treat cells. AZD7507 CSF1R has been previously described (Scott et al., 2013) . FCCP, oligomycin, rotenone, antimycin A were from Sigma-Aldrich and stocks were prepared in DMSO; etomoxir, carnitine, palmitate, were from Sigma-Aldrich and prepared in water, BSA fraction V was from Roche and prepared in water.
Cell Viability Assay: PDAC cells were grown on white walled 96-well plates (Costar 3917, Corning) at 1000 cells/well in triplicate and grown for four days. Cell viability was measured using the Cell Titer Glo 2.0 luminescence assay (Promega G9243). Luminescence was measured for 500ms using a SpectraMax M3 Microplate reader (Molecular Devices). IC50 values were calculated using GraphPad Prism 7.
Metabolic Flux Assay: To estimate the rate of glycolysis and mitochondrial respiration, a Seahorse Metabolic Flux Analyzer e96 XF instrument (Agilent) was used according to the manufacturer's suggestion. 50,000 cells/well were seeded in the respective polarization culture media the day prior to the assay. The next day media was exchanged to the Seahorse assay media, containing 25 mM glucose, adjusted to pH~7.4. The cell plate was allowed to equilibrate for 1 hour in a non-CO2, 37°C incubator, followed by 3 sequential measurements for the basal respiration. The mitostress assay was performed by sequentially injecting 2μM oligomycin, 5μM FCCP, 0.5μM rotenone/0.5μM antimycin A. The cell number adjustment/normalization was performed using CyQuant NF (Thermo) after the assay.
Seahorse Fatty Acid Oxidation Assay: Macrophages were polarized as described above. BSApalmitate conjugates were prepared and the FAO assay was performed according to the manufacturer's application notes with the following modifications: 50,000 cells/well supplied with the corresponding polarization factors in 5 replicates seeded the night before the assay.
Incubation with the substrate-limiting media was omitted. The next day cells were washed twice with FAO media and incubated in for 1 hour in non-CO2 incubator. Etomoxir was added to final concentration 40μM to the corresponding control wells, cells were incubated for 15 mins, BSA-Palmitate or BSA were added immediately before the assay. The level of exogenous FAO was calculated as a difference between BSA-Palmitate and Etomoxir-Palmitate, and the respiration attributed to the proton leak was accounted for.
Metabolic Pathway Analysis: Metabolic pathway enrichment analysis was performed using metabolites determined to be significant between M1 macrophages, M2 macrophages, and TEMs by two-tailed t-test with a significance threshold level of 0.05 using Metabolanalyst online software (http://www.metaboanalyst.ca/). RNAi: ON-TARGETplus siRNAs targeted toward murine Dhodh, Umps, or nontargeting sequence were purchased from Dharmacon. siRNAs were transfected into RAW246.7 cells using Lipofectamine RNAiMAX (ThermoFisher) per the manufacturer's instructions. Media was changed to iKras*3 PDA conditioned media after 48 hours and allowed to condition for 48 additional hours. Media was then collected and filtered through a 0.45µM filter prior to use.
Western blotting: Lysates were quantified by BCA assay (Thermo Fisher Scientific Inc., Waltham, MA) and equal protein amounts were run onto SDS-PAGE gels. Proteins were transferred from SDS-PAGE gel to Immobilon-FL PVDF membrane, blocked, then incubated with primary antibodies. After washing, membranes were then incubated in secondary antibody washed, then exposed on autoradiography film (Bioexpress) with West Pico ECL (Thermo Mouse strains: Kras +/G12D ; Pdx1-Cre; Trp53 +/R172H (KPC) mice have been previously described (Hingorani et al., 2005) . KPC animal experiments were performed under UK Home Office license and approved by the University of Glasgow animal welfare and ethical review committee. Mice were bred in house on a mixed background, maintained in conventional cages with access to standard diet and water ad libitum, and genotyped by Transnetyx (Cordoba, TN, USA). Mice of both sexes were randomly assigned to treatment cohorts at 10 weeks of age and treated with Gemcitabine (LC Labs) at 100mg/kg i.p. twice weekly +/-AZD7507 CSF1R inhibitor Histology: Mice were sacrificed by CO2 asphyxiation then tissue was quickly harvested and fixed overnight at room temperature with Z-fix solution (Anatech LTD). Tissues were processed using a Leica ASP300S Tissue Processor, paraffin embedded, and cut into 5 µm sections.
Immunohistochemistry was performed on Discovery Ultra XT autostainer (Ventana Medical
Systems Inc) and counterstained with hematoxylin. IHC slides were scanned on a Pannoramic SCAN slide scanner (Perkin Elmer), and annotation regions encompassing greater than 1mm of tissue were processed using Halo software (Indica Labs).
Patient survival data: Patients were identified from the Australian Pancreatic Genome Initiative's (APGI) contribution to the International Cancer Genome Consortium's Pancreatic Cancer project (Dreyer et al., 2018) . Patients with sufficient clinical data that underwent RNA sequencing (RNAseq) and analysis were included. All patients included underwent primary surgical resection for PDA and were defined as receiving Gemcitabine-based adjuvant therapy if completing 3 cycles or more. RNAseq and analysis was performed as previously described (Bailey et al., 2016) . Macrophage infiltration signature was determined by gene enrichment analysis that defined upregulated gene expression associated with macrophage infiltration (Bailey et al., 2016; Rooney et al., 2015) . Patients were dichotomized as high or low signature based on ranking the relative signature score from highest to lowest (Bailey et al., 2016) .
Clinical variables were determined using the AJCC 7 th staging system. Survival analysis was performed using the log-rank test using SPSS (Version 22.0; IBM SPSS Statistics, IBM Corporation, Armonk, NY). Deidentified patient data are provided in Supplemental Data Table 4 .
Statistical analysis: Statistics were performed using Graph Pad Prism 7 (Graph Pad Software Inc). Groups of 2 were analyzed with two-tailed students t test, groups greater than 2 with a single variable were compared using one-way ANOVA analysis with Tukey post hoc test, and groups greater than two multiple variables were compared with two-way AVONA with Tukey post hoc test. All error bars represent mean with standard deviation. H.
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